Microsoft Word - MD&A Q1_2020 (Eng ) May 8, 2020 Subject : Interim Management Discussion and Analysis of Q1/2020 Attention : President of The Stock Exchange of Thailand We attach herewith the
MD&A Q2_2020 (Eng ) July 31, 2020 Subject : Interim Management Discussion and Analysis of Q2/2020 Attention : President of The Stock Exchange of Thailand We attach herewith the financial statements
3323 No. PACE IR 2020/01 Date: 25 August 2020 Subject: Explanation of the Operating Results for the three-month period ended 30 September 2019 changing over 20% To: The President The Stock Exchange of
[COMPANY NAME] Ref.: EFORL IR037/2020 September 11, 2020 Subject: Management Discussion and Analysis Quarter 2 Ending 30 June 2020 To President The Stock Exchange of Thailand 1. Overview financial
MD&A Q3_2020 (Eng ) November 2, 2020 Subject : Interim Management Discussion and Analysis of Q3/2020 Attention : President of The Stock Exchange of Thailand We attach herewith the financial
April 27th, 2021 No. ACC/HO 008/64 Topic: Management Discussion and Analysis for the Quarter of 1/2021 To: President The Stock Exchange of Thailand During the first quarter of 2021 a new wave of
Discussion and Analysis, Quarter 1 Ending 31 March 2020 (4) The Impact of the COVID-19 situation To: President of the Stock Exchange of Thailand Reference: (1) Document no. Tor. For. 4/2020 dated April 10
August 11, 2020 Subject: Management’s Discussion and Analysis for the second Quarter of 2020 To: The President The Stock Exchange of Thailand (SET) DOD Biotech Public Company Limited and its subsidiaries
-9320 1 Ref: PCL 2020/018 November 14, 2020 Subject: Management Discussion and Analysis for the 9-month period ended 30 September 2020 To: The President of the Stock Exchange of Thailand Panjawattana
MDA Q3_2019 (Eng ) November 8, 2019 Subject : Interim Management Discussion and Analysis of Q3/2019 Attention : President of The Stock Exchange of Thailand We attach herewith the financial statements